PASADENA, Calif.--(BUSINESS WIRE)--Nov. 1, 2018--
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to present at the following upcoming events:
BIT’s 16th Annual Congress of International Drug Discovery Science
and Technology– Jinan, China, November 6-8, 2018
November 6, 11:20 a.m. CST –Zhen Li, Ph.D., Arrowhead’s senior
vice president of chemistry and non-clinical development, will deliver a
keynote presentation titled, “Discovery and Development of Arrowhead
Clinical Candidates ARO-AAT and ARO-HBV”
International HBV Cure Workshop 2018 – Toronto, November 7, 2018
November 7, 3:35 p.m. EST –Bruce Given, M.D., Arrowhead’s chief
operating officer, will deliver an oral presentation titled, “Clinical
update on reducing HBV virus and antigen production using RNAi”
The Search for HBV / HDV Cure: Challenges for Industry– San
Francisco, November 9, 2018
November 9, 11:15 a.m. PST – Dr. Given will deliver an oral
presentation titled, “AROHBV1001 Results Update”
The Liver Meeting® 2018, the Annual Meeting of the American
Association for the Study of Liver Disease– San Francisco, November
9-13, 2018
November 12, 8:00 a.m. to 5:30 p.m. PST – Dr. Edward J. Gane, et
al., will deliver a late-breaking poster presentation titled, “First
Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using
ARO-HBV”
November 12, 8:00 a.m. to 5:30 p.m. PST – Dr. Christian Schwabe,
et al., will deliver a late-breaking poster presentation titled, “A
Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the
Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum
Alpha-1 Antitrypsin levels in Normal Adult Volunteers”
American Heart Association Scientific Sessions 2018 – Chicago,
November 10-12, 2018
November 12, 10:45 a.m. CST –Rui Zhu, Ph.D., Arrowhead’s senior
chemist, will deliver an oral presentation titled, “RNA Interference
Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for
Hypertriglyceridemia”
November 12, 11:45 a.m. CST – So Wong, Ph.D., Arrowhead’s
director of oncology, will deliver an oral presentation titled, “Development
of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3
for Treatment of Hyperlipidemia”
30th EORTC-NCI-AACR Symposium – Dublin,
November 13-16, 2018
November 13, 10:00 a.m. GMT – Dr. Given will deliver a poster
presentation titled, “Targeting HIF2α with an RNAi therapeutic for
the treatment of clear cell renal cell carcinoma”
Jefferies 2018 London Healthcare– London, November 14-15, 2018
November 15, 2:00 p.m. GMT –Christopher Anzalone, Ph.D.,
Arrowhead’s president and chief executive officer, will deliver a
corporate presentation
China Nucleic Acids – Guangzhou, China, November 15-16, 2018
November 16, 11:20 – Dr. Li will deliver an oral presentation
titled, “TRiMTM Platform Based RNAi
Therapeutics for AATD and Cardiometabolic Diseases”
30th Annual Piper Jaffray Healthcare Conference– New York,
November 27-29, 2018
November 28, 3:30 p.m. EST – Dr. Anzalone will participate in a
fireside chat
A copy of the presentation materials and webcast links, if the
presentation is being webcast, may be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company's email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the likelihood and
timing of the receipt of future milestone and licensing fees, the future
success of our scientific studies, our ability to successfully develop
and commercialize drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation
to update or revise forward-looking statements to reflect new events or
circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005234/en/
Source: Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
